Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Drugs In Development, 2022, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.
Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 2, 21, 17, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 6, 1 and 1 molecules, respectively.
Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Drugs In Development, 2022, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.
Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 2, 21, 17, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 6, 1 and 1 molecules, respectively.
Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Pontine Glioma - Overview
Pontine Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pontine Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pontine Glioma - Companies Involved in Therapeutics Development
Pontine Glioma - Drug Profiles
8H-9 - DRUG PROFILE
Product Description
Mechanism Of Action
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
ACT-001 - Drug Profile
Product Description
Mechanism Of Action
Alocelyvir - Drug Profile
Product Description
Mechanism Of Action
AMXT-1501 + eflornithine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
BXQ-350 - Drug Profile
Product Description
Mechanism Of Action
Cabometyx - Drug Profile
Product Description
Mechanism Of Action
CBL-0137 - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Diffuse Intrinsic Pontine Glioma and Glioblastoma - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
cemiplimab - Drug Profile
Product Description
Mechanism Of Action
cobimetinib fumarate - Drug Profile
Product Description
Mechanism Of Action
disufenton sodium - Drug Profile
Product Description
Mechanism Of Action
doxorubicin - Drug Profile
Product Description
Mechanism Of Action
ensartinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
everolimus - Drug Profile
Product Description
Mechanism Of Action
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
G2B-001 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target B7H3 for CNS Tumor - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target GD-2 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
indoximod - Drug Profile
Product Description
Mechanism Of Action
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
Kid EDV - Drug Profile
Product Description
Mechanism Of Action
larotrectinib sulfate - Drug Profile
Product Description
Mechanism Of Action
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
MANA-677679 - Drug Profile
Product Description
Mechanism Of Action
marizomib - Drug Profile
Product Description
Mechanism Of Action
MDNA-55 - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody Conjugate to Target B7H3 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
nimotuzumab - Drug Profile
Product Description
Mechanism Of Action
nivolumab - Drug Profile
Product Description
Mechanism Of Action
omburtamab - Drug Profile
Product Description
Mechanism Of Action
ONC-201 - Drug Profile
Product Description
Mechanism Of Action
ORX-101 - Drug Profile
Product Description
Mechanism Of Action
P-28 - Drug Profile
Product Description
Mechanism Of Action
palbociclib - Drug Profile
Product Description
Mechanism Of Action
panobinostat - Drug Profile
Product Description
Mechanism Of Action
panobinostat SR - Drug Profile
Product Description
Mechanism Of Action
paxalisib - Drug Profile
Product Description
Mechanism Of Action
pomalidomide - Drug Profile
Product Description
Mechanism Of Action
RG-2833 - Drug Profile
Product Description
Mechanism Of Action
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
RNL - Drug Profile
Product Description
Mechanism Of Action
S-588410 - Drug Profile
Product Description
Mechanism Of Action
selinexor - Drug Profile
Product Description
Mechanism Of Action
SL-701 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit ACVR1 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
sotigalimab - Drug Profile
Product Description
Mechanism Of Action
SurVaxM - Drug Profile
Product Description
Mechanism Of Action
tasadenoturev - Drug Profile
Product Description
Mechanism Of Action
trabedersen - Drug Profile
Product Description
Mechanism Of Action
unesbulin - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Glioma - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
Vaccine to Target CMV Antigen for Central Nervous System Cancer - Drug Profile
Product Description
Mechanism Of Action
WP-1066 - Drug Profile
Product Description
Mechanism Of Action
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
Pontine Glioma - Dormant Projects
Pontine Glioma - Discontinued Products
Pontine Glioma - Product Development Milestones
Featured News & Press Releases
Nov 20, 2022: Oncotelic prresenting data for OT101 against diffuse intrinsic pontine glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
Oct 06, 2022: PNOC clinical study of kazia's paxalisib in childhood brain cancer expands internationally
Jun 21, 2022: Orphan Designation granted by EMA to MTX110 development for the treatment of Glioma
Jun 15, 2022: Midatech Pharma : An update to MTX110 study in pediatric patients with DIPG to be presented at The International Symposium on Pediatric Neuro-Oncology, Hamburg, Germany (ISPNO 2022)
Nov 22, 2021: DNAtrix announces oral presentation of positive overall survival data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) annual meeting
Aug 13, 2021: Plus Therapeutics to present data from ReSPECT-GBM trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting
Jul 19, 2021: Oblato announces that it has received a positive response from the FDA for the use of OKN-007 for patients with high-grade gliomas in an expanded access program
Jul 07, 2021: The new immunomodulator ACT001 shows great potential
Apr 29, 2021: Y-mAbs announces Omburtamab data to be presented at 2021 ASCO annual meeting
Mar 25, 2021: Midatech Pharma announces MTX110 update & headline results for 2020
Mar 03, 2021: Oblato announces Fast Track Designation of OKN-007 for diffuse intrinsic pontine glioma from the FDA
Dec 11, 2020: Midatech Pharma announces MTX110 Ppogrammes to be presented at ISPNO 2020
Dec 10, 2020: Oblato announces discussion outcome with FDA for development of OKN-007 for diffuse intrinsic pontine glioma
Dec 10, 2020: Kazia to collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for new Paxalisib combination study in DIPG
Dec 01, 2020: Moleculin announces FDA approves 3 rare pediatric disease designations for WP1066
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Pontine Glioma - Overview
Pontine Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pontine Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pontine Glioma - Companies Involved in Therapeutics Development
Pontine Glioma - Drug Profiles
8H-9 - DRUG PROFILE
Product Description
Mechanism Of Action
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
ACT-001 - Drug Profile
Product Description
Mechanism Of Action
Alocelyvir - Drug Profile
Product Description
Mechanism Of Action
AMXT-1501 + eflornithine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
BXQ-350 - Drug Profile
Product Description
Mechanism Of Action
Cabometyx - Drug Profile
Product Description
Mechanism Of Action
CBL-0137 - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Diffuse Intrinsic Pontine Glioma and Glioblastoma - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
cemiplimab - Drug Profile
Product Description
Mechanism Of Action
cobimetinib fumarate - Drug Profile
Product Description
Mechanism Of Action
disufenton sodium - Drug Profile
Product Description
Mechanism Of Action
doxorubicin - Drug Profile
Product Description
Mechanism Of Action
ensartinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
everolimus - Drug Profile
Product Description
Mechanism Of Action
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
G2B-001 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target B7H3 for CNS Tumor - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target GD-2 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
indoximod - Drug Profile
Product Description
Mechanism Of Action
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
Kid EDV - Drug Profile
Product Description
Mechanism Of Action
larotrectinib sulfate - Drug Profile
Product Description
Mechanism Of Action
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
MANA-677679 - Drug Profile
Product Description
Mechanism Of Action
marizomib - Drug Profile
Product Description
Mechanism Of Action
MDNA-55 - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody Conjugate to Target B7H3 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
nimotuzumab - Drug Profile
Product Description
Mechanism Of Action
nivolumab - Drug Profile
Product Description
Mechanism Of Action
omburtamab - Drug Profile
Product Description
Mechanism Of Action
ONC-201 - Drug Profile
Product Description
Mechanism Of Action
ORX-101 - Drug Profile
Product Description
Mechanism Of Action
P-28 - Drug Profile
Product Description
Mechanism Of Action
palbociclib - Drug Profile
Product Description
Mechanism Of Action
panobinostat - Drug Profile
Product Description
Mechanism Of Action
panobinostat SR - Drug Profile
Product Description
Mechanism Of Action
paxalisib - Drug Profile
Product Description
Mechanism Of Action
pomalidomide - Drug Profile
Product Description
Mechanism Of Action
RG-2833 - Drug Profile
Product Description
Mechanism Of Action
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
RNL - Drug Profile
Product Description
Mechanism Of Action
S-588410 - Drug Profile
Product Description
Mechanism Of Action
selinexor - Drug Profile
Product Description
Mechanism Of Action
SL-701 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit ACVR1 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
sotigalimab - Drug Profile
Product Description
Mechanism Of Action
SurVaxM - Drug Profile
Product Description
Mechanism Of Action
tasadenoturev - Drug Profile
Product Description
Mechanism Of Action
trabedersen - Drug Profile
Product Description
Mechanism Of Action
unesbulin - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Glioma - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
Vaccine to Target CMV Antigen for Central Nervous System Cancer - Drug Profile
Product Description
Mechanism Of Action
WP-1066 - Drug Profile
Product Description
Mechanism Of Action
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
Pontine Glioma - Dormant Projects
Pontine Glioma - Discontinued Products
Pontine Glioma - Product Development Milestones
Featured News & Press Releases
Nov 20, 2022: Oncotelic prresenting data for OT101 against diffuse intrinsic pontine glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
Oct 06, 2022: PNOC clinical study of kazia's paxalisib in childhood brain cancer expands internationally
Jun 21, 2022: Orphan Designation granted by EMA to MTX110 development for the treatment of Glioma
Jun 15, 2022: Midatech Pharma : An update to MTX110 study in pediatric patients with DIPG to be presented at The International Symposium on Pediatric Neuro-Oncology, Hamburg, Germany (ISPNO 2022)
Nov 22, 2021: DNAtrix announces oral presentation of positive overall survival data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) annual meeting
Aug 13, 2021: Plus Therapeutics to present data from ReSPECT-GBM trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting
Jul 19, 2021: Oblato announces that it has received a positive response from the FDA for the use of OKN-007 for patients with high-grade gliomas in an expanded access program
Jul 07, 2021: The new immunomodulator ACT001 shows great potential
Apr 29, 2021: Y-mAbs announces Omburtamab data to be presented at 2021 ASCO annual meeting
Mar 25, 2021: Midatech Pharma announces MTX110 update & headline results for 2020
Mar 03, 2021: Oblato announces Fast Track Designation of OKN-007 for diffuse intrinsic pontine glioma from the FDA
Dec 11, 2020: Midatech Pharma announces MTX110 Ppogrammes to be presented at ISPNO 2020
Dec 10, 2020: Oblato announces discussion outcome with FDA for development of OKN-007 for diffuse intrinsic pontine glioma
Dec 10, 2020: Kazia to collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for new Paxalisib combination study in DIPG
Dec 01, 2020: Moleculin announces FDA approves 3 rare pediatric disease designations for WP1066
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Pontine Glioma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pontine Glioma - Dormant Projects, 2022
Pontine Glioma - Discontinued Products, 2022
Number of Products under Development for Pontine Glioma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pontine Glioma - Dormant Projects, 2022
Pontine Glioma - Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development for Pontine Glioma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Number of Products under Development for Pontine Glioma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
